 The FDA has removed the clinical hold on GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Incs NASDAQ: RARE GTX-102 trial for Angelman syndrome. The companies can begin dosing naïve patients in the Phase 12 study of GTX-102 in pediatric patients. 